NTRK
InnoCare Pharma Seeking Zurletrectinib Approval in NTRK Fusion-Positive Tumors in China
The firm submitted data from a registrational study showing the drug's activity in adult and adolescent patients with NTRK fusion-positive solid tumors.
FDA Grants Full Approval to Bayer's Vitrakvi in NTRK-Positive Solid Tumors
The 2018 accelerated approval of Vitrakvi was converted to full approval based on results from three trials in adult and pediatric patients.
Tissue-Agnostic Trial Shows Frontline Vitrakvi Benefit in NTRK-Positive Pediatric Solid Tumors
In the Phase II ADVL1823 study, researchers evaluated Vitrakvi in children with newly diagnosed IFS and other solid tumors with NTRK fusions.
Avistone Biotechnology to Begin Trial of Next-Generation ROS1/NTRK Inhibitor
The firm will study ANS03 in patients with tumors harboring a ROS1 or NTRK alteration, including those with acquired resistance mutations.
CHMP Recommends BMS's Augtyro for ROS1-Positive NSCLC, NTRK-Positive Tumors
The European Commission will decide whether to approve Augtyro in these two indications in January 2025.
Feb 16, 2022